[Malignant primary peritoneal tumors].
Malignant primary peritoneal tumors are rare and should be kept in mind when peritoneal carcinomatosis is diagnosed without primary tumor found. The principal etiologies are peritoneal mesthelioma, pseudomyxoma peritonei and primary peritoneal serous carcinoma. Their diagnosis requires most of the time biopsy performing by laparoscopy that should prevent tumoral parietal diffusion (port sites on the middle line). The treatment of reference combines optimal cytoreductive surgery and perioperative intraperitoneal chemotherapy when general status allows performing it. The management of these diseases should be done into specialized centers, included into national network (RENAPE), because of specificity and complexicity of treatments and to facilitate clinical and fundamental research on rare disease.
Cotte
Eddy
E
Service de chirurgie générale, thoracique et endocrinienne, Centre hospitalier Lyon-Sud, F-69495 Pierre Bénite Cedex, France.
Passot
Guillaume
G
Isaac
Sylvie
S
Gilly
François-Noël
FN
Glehen
Olivier
O
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001706:Biopsy; D002173:Cancer Care Facilities; D010478:Chemotherapy, Cancer, Regional Perfusion; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D008875:Middle Aged; D009367:Neoplasm Staging; D010534:Peritoneal Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D010537:Peritoneum / Q000473:pathology; D011379:Prognosis; D011553:Pseudomyxoma Peritonei / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology / Q000601:surgery